Pharmaceutical patent issue emerged as a key KORUS FTA agenda.

The pharmaceutical patent issues have been surfaced to the Korea and U. S. free trade agreement (FTA) as a key agenda.

In a few round of the KORUS FTA talks in Washington DC, the U. S. side called for the patent to be linked with the health registration of new drugs and for the generic drug approvals to be controlled within the valid terms of its patent protection.

The U. S. side also re...